Drug
Zavegepant clinical trials
Also written BHV3500.
- studies test it
- 18
- open now
- 5
- in phase 3
- 7
- first study started
- 2019
Keep track of what changes. Save the zavegepant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Other names
Studies by the year they started
18 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 5
- Phase 3
- 7
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 5
Pfizer (13) · American Center for Psychiatry and Neurology (1) · The University of Texas Health Science Center, Houston (1) · University of South Florida (1) · Mayo Clinic (1) · Icahn School of Medicine at Mount Sinai (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses zavegepant is read from its arms, and is right about nine times in ten.
Testing it · 18
- A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of MigraineNot yet recruitingNot applicableAmerican Center for Psychiatry and NeurologyNCT07861412Written as intranasal zavegepant
- Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster HeadacheNot yet recruitingPhase 2The University of Texas Health Science Center, HoustonNCT07714369Written as Zavegepant 20 mg
- A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of MigraineRecruitingPhase 1PfizerNCT06995729Written as Zavegepant
- Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive MedicationsRecruitingPhase 4Mayo ClinicNCT06401642Written as Zavegepant
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency DepartmentNot yet recruitingPhase 1University of South FloridaNCT07667621Written as Zavegepant
- A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian AdultsCompletedPhase 3PfizerNCT05989048Written as Zavegepant
- Acute Migraine Treatment in the ED With GepantsTerminatedPhase 4Icahn School of Medicine at Mount SinaiNCT06985342Written as Zavegepant
- A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric MicrosamplingCompletedPhase 1PfizerNCT05948085Written as Zavegepant 10 mg IN
- A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult ParticipantsWithdrawnPhase 3PfizerNCT06103734Written as Zavegepant 10 mg
- A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine PreventionTerminatedPhase 2/3PfizerNCT04804033Written as BHV-3500 (zavegepant)
- A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult ParticipantsCompletedPhase 1PfizerNCT05960032Written as Zavegepant
- A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding WomenCompletedPhase 1PfizerNCT06453356Written as Zavegepant 10mg
- A Study to Learn About the Study Medication, Zavegepant, in Healthy VolunteersCompletedPhase 1PfizerNCT06137703Written as Zavegepant 100mg non-enteric coated soft gel capsule
- Safety and Efficacy Active Drug vs. Placebo in Subjects With AsthmaTerminatedPhase 1PfizerNCT04987944Written as Zavegepant
- Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental OxygenTerminatedPhase 2/3PfizerNCT04346615Written as Zavegepant (BHV-3500)
- Acute Treatment Trial in Adult Subjects With MigrainesCompletedPhase 2/3PfizerNCT03872453Written as Zavegepant
- Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of MigraineCompletedPhase 2/3PfizerNCT04408794Written as Zavegepant (BHV-3500)
- Randomized Trial in Adult Participants With Acute MigrainesCompletedPhase 3PfizerNCT04571060Written as Zavegepant
Codes
What other systems call zavegepant · ClinicalTrials.gg INT006389
- MeSH (NLM) C584752zavegepantOne source NLM
- UNII (FDA) ODU3ZAZ94JZAVEGEPANTConfirmed FDA, NLM, Wikidata
- Wikidata Q99388898zavegepantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C172616ZavegepantOne source FDA
- DrugBank DB15688One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584752 | zavegepant | One source NLM |
| UNII (FDA) | ODU3ZAZ94J | ZAVEGEPANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q99388898 | zavegepant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C172616 | Zavegepant | One source FDA |
| DrugBank | DB15688 | — | One source Wikidata |
Also registered as zavegepant hydrochloride (UNII 000QCM6HAL).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.